Galois Theory

por Cox, David A
Publicado 2012

Primes of the form x2+ny2: Fermat, class field theory, and complex multiplication

por Cox, David A
Publicado 2014

Applications of polynomial systems

por Cox, David A
Publicado 2020

Mirror symmetry and algebraic geometry

por Cox, David A, Katz, Sheldon
Publicado 2014

Mirror symmetry and algebraic geometry

por Cox, David A, Katz, Sheldon
Publicado 1999

Residues and duality for projective algebraic varieties

por Kunz, Ernst, Cox, David A, Dickenstein, Alicia
Publicado 2008

Using algebraic geometry

por Cox, David A, Little, John, O’shea, Donal
Publicado 2005

Ideals, varieties, and algorithms: an introduction to computational algebraic geometry and commutative algebra

por Cox, David A, Little, John, O'Shea, Donal
Publicado 2015

Toric varieties

por Cox, David A, Little, John B, Schenck, Henry K
Publicado 2011

Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk...

por Cox, David A., Wang, Hui, Nicolay, Claudia, Bethel, Mary Angelyn
Publicado 2022

A Review of Interventional Trials in Youth-Onset Type 2 Diabetes: Challenges and Opportunities

por Currie, Brooke M., Howell, Timothy A., Matza, Louis S., Cox, David A., Johnston, Joseph A.
Publicado 2021

Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11

por Frias, Juan Pablo, Bonora, Enzo, Cox, David A, Kwan, Anita, Raha, Sohini, Bethel, Angelyn, Malik, Raleigh
Publicado 2021

OR26-08 Efficacy and Safety of Higher Dulaglutide Doses (3.0 MG and 4.5 MG) When Added to Metformin in Patients With Type 2 Diabetes: A Phase 3, Randomized, Double-Blind, Parallel...

por Frias, Juan Pablo, Ruiz, Luis Nevárez, Li, Ying Grace, Yu, Zhuoxin, Milicevic, Zvonko, Woodward, Brad, Cox, David A
Publicado 2020

Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11

por Frias, Juan P., Bonora, Enzo, Cox, David A., Bethel, M. Angelyn, Kwan, Anita Y.M., Raha, Sohini, Malik, Raleigh E.
Publicado 2021

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

por Frias, Juan P., Bonora, Enzo, Nevarez Ruiz, Luis, Li, Ying G., Yu, Zhuoxin, Milicevic, Zvonko, Malik, Raleigh, Bethel, M. Angelyn, Cox, David A.
Publicado 2021

Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial

por Frias, Juan P., Bonora, Enzo, Nevárez Ruiz, Luis, Hsia, Stanley H., Jung, Heike, Raha, Sohini, Cox, David A., Bethel, M. Angelyn, Konig, Manige
Publicado 2021

Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11

por Bonora, Enzo, Frias, Juan P., Tinahones, Francisco J., Van, Joanna, Malik, Raleigh E., Yu, Zhuoxin, Mody, Reema, Bethel, Angelyn, Kwan, Anita Y. M., Cox, David A.
Publicado 2021

Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta‐analysis of disease progression rates in recent multicenter clinical trials

por McDonald, Craig M., Sajeev, Gautam, Yao, Zhiwen, McDonnell, Erin, Elfring, Gary, Souza, Marcio, Peltz, Stuart W., Darras, Basil T., Shieh, Perry B., Cox, David A., Landry, John, Signorovitch, James
Publicado 2019